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ABSTRACT
Background: High attendance rates and regular participation in disease screening programs are important
contributors to program eﬀectiveness. The objective of this study was to examine the eﬀects of an initial false-
positive result in chest X-ray screening for lung cancer on subsequent screening participation.
Methods: This historical cohort study analyzed individuals who ﬁrst participated in a lung cancer screening
program conducted by Yokohama City between April 2007 and March 2011, and these participants were
retrospectively tracked until March 2013. Subsequent screening participation was compared between participants
with false-positive results and those with negative results in evaluation periods between 365 (for the primary
outcome) and 730 days. The association of screening results with subsequent participation was evaluated using a
generalized linear regression model, with adjustment for characteristics of patients and screening.
Results: The proportions of subsequent screening participation within 365 days were 12.9% in 3132 participants
with false-positive results and 6.7% in 15 737 participants with negative results. Although the diﬀerences in
attendance rates were reduced with longer cutoﬀs, participants with false-positive results were consistently more
likely to attend subsequent screening than patients with negative results (P < 0.01). The predictors of subsequent
screening participation were false-positive results (risk ratio [RR] 1.72; 95% conﬁdence interval [CI], 1.54–1.92),
older age (RR 1.17; 95% CI, 1.11–1.23), male sex (RR 1.46; 95% CI, 1.29–1.64), being a current smoker (RR 0.80;
95% CI, 0.69–0.93), current employment (RR 0.79; 95% CI, 0.70–0.90), and being screened at a hospital cancer
center (vs public health centers; RR 1.36; 95% CI, 1.15–1.60).
Conclusions: Our ﬁndings indicated that subsequent participation in lung cancer screening was more likely among
participants with false-positive results in an initial screening than patients with negative results.
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INTRODUCTION
Lung cancer is one of the leading causes of death from cancer
for men and women in Japan.1 As patients with lung cancer
are at risk of poor prognosis, early detection and treatment
are important for successful disease management. Chest X-ray
screening for lung cancer has been recommended by the
Ministry of Health, Labour and Welfare and has been widely
implemented by Japanese local governments2,3 based on the
association of the screening with reductions in lung cancer
mortality by approximately 30% to 60% from case-control
studies performed in diﬀerent regions of Japan.4–10
In Japan, attendance rates for various cancer screenings are
generally low, and this has been recognized as an important
issue.11 Low rates of initial participation and of re-attendance
to screenings may compromise the eﬀectiveness of screening
programs. Studies conducted in breast cancer screening
have shown that false-positive results in previous screenings
can aﬀect participation in subsequent screenings.12–14 In a
systematic review of mammography screening for breast
cancer, participants with false-positive results were found to
be more likely to attend subsequent screenings in the United
States but less likely in Europe and Canada.14 For lung cancer
screening, false-positive results were identiﬁed as a negative
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predictor of subsequent screening attendance for participants
in a randomized controlled trial, the Prostate, Lung,
Colorectal, and Ovarian Cancer Screening Trial (PLCO).15
However, further conﬁrmation of those ﬁndings are needed,
since the behavior of participants in a screening trial may
diﬀer from that in actual clinical practice. In addition, false-
positive results in screenings may engender unnecessary risks
of physical or psychological complications associated with
additional examinations.12–14,16 Therefore, the objective of
this study was to examine the eﬀects of initial false-positive
results in chest X-ray screening for lung cancer on subsequent
screening participation in a general community population.
METHODS
Lung cancer screening in Yokohama City
Since 1981, Yokohama City (with approximately 3.7 million
residents) has conducted an annual lung cancer screening
program using chest X-ray. The target subjects for screening
comprised residents aged 40 years and older who did not have
the opportunity to attend cancer screening at their workplace
or who were unemployed residents. Participants with a
smoking index of 400 or more were oﬀered an optional
sputum cytology test.
Screening institutions included the Cancer Center of
Yokohama Municipal Citizen’s Hospital (CC-YMCH) and 18
Public Health and Welfare Centers (PHWC), which are located
in each ward. In this study, we focused on the screening
at these institutions provided by the local government of
Yokohama City but did not include private complete medical
check-ups and screenings conducted by other institutions. The
screening fees (subsidized by Yokohama City) in 2014 were
680 or 1350 yen (approximately 6.8 or 13.5 United States
dollars) for chest X-ray only or for both chest X-ray and
sputum cytology test, respectively. These fees were waived
for participants aged 70 years and older and for those who
were from low-income families. In this way, Yokohama City
supports candidate screening participants through subsidies to
cover part or all of the screening costs.
The ﬂow of the lung cancer screening process in Yokohama
City is shown in Figure 1. There were two lung cancer
screening systems: one was conducted in the 18 PHWCs, and
the other was conducted in the CC-YMCH. In the PHWC
system, a public health physician and a primary care physician
independently read chest radiographs (posterior-anterior and
lateral views). Two pulmonologists at the CC-YMCH also
independently read the same chest radiographs. These four
physicians performed comparative readings of current and
previous chest radiographs, if available. If any one of the four
physicians detected an abnormality, the radiographs were
reviewed in an expert meeting that involved pulmonologists
from the CC-YMCH and physicians from the PHWCs, and
the need for further investigations was determined. If
participants initially received an indirect radiograph, further
investigation included direct radiographs or chest computed
tomography (CT) scans. If participants initially received direct
radiographs, further investigation involved chest CT scans.
In the CC-YMCH system for lung cancer screening, two
pulmonologists independently read the direct radiographs. If
at least one physician determined a positive result, further
investigations were performed without an expert meeting.
Results of the screening were classiﬁed into ﬁve categories
(“a” to “e”) according to guides published by the Japan Lung
Cancer Society2,17,18; the categories of “suspicious (e2)” or
“possible (e1)” were considered positive results. Suspicious
noncancerous lesions that required further examination were
categorized as “d”. Suspicious noncancerous lesions that
did not require further examination were categorized as
“c”. Normal chest radiographs were categorized as “b” and
radiographs that were inadequate for reading were categorized
as “a”.
Participants were informed of their screening results via
mail. Participants with negative results were encouraged to
attend screening 1 year later. Participants with positive results
were asked to undergo work-up examinations by mail and/or
telephone by public health nurses. As a result, almost all
participants in the screening program with positive results
(>97%) underwent work-up examinations. After screening, all
screening records were collected and stored at the CC-YMCH.
Study design and population
We conducted a historical cohort study to analyze participants
aged 40–79 years who had attended lung cancer screening
for the ﬁrst time between April 2007 and March 2011 in
Yokohama City. First-time participants were deﬁned as those
with no record of screening results from lung cancer screening
conducted at a PHWC or the CC-YMCH within the preceding
5 years. Participants were excluded from analysis if they
fulﬁlled any of the following criteria: participants who did not
attend any work-up examinations; participants who had been
diagnosed with lung cancer in the past; and participants with
bloody sputum at the primary screening, as these participants
were supposed to receive work-up examinations regardless of
their chest X-ray screening results. Participants were tracked
until March 2013, and, as a result, all participants were
observed for a minimum of 2 years.
Prior to conducting this study, written informed consent
was obtained from all screening participants for the use of
their screening records for research purposes. The study
protocol was approved (Approval Number E1884) by Kyoto
University Graduate School and Faculty of Medicine Ethics
Committee and the Institutional Review Board of Yokohama
Municipal Citizen’s Hospital.
Deﬁnitions
Primary screening included chest X-ray (indirect or direct
radiograph) with or without additional sputum cytology.
Work-up examinations included additional chest X-ray (direct
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radiograph), chest CT scan, and bronchoscopy. Participants
were classiﬁed into false-positive, negative, and true-positive
groups according to their screening results. Participants with
either true-negative or false-negative results in the primary
screening were collectively classiﬁed into the negative group,
as we were unable to distinguish between these participants
due to insuﬃcient follow-up records. Due to the low
prevalence of lung cancer in screened individuals,
participants with false-negative results were expected to
account for a very small proportion of the sample. The
inclusion of these participants in the negative group is
therefore unlikely to have a substantial impact on the results
of the study.
Participants with false-positive results were deﬁned as those
who had positive results after the expert meeting in the
primary screening but were not subsequently diagnosed with
lung cancer. Participants without deﬁnitive diagnoses within
365 days of the ﬁrst date of work-up examination visit were
also included in the false-positive group. Participants with
true-positive results were deﬁned as those who were
diagnosed with lung cancer within 365 days of the ﬁrst date
of work-up examination visit.
Outcomes and measurements
The primary outcome measure was subsequent screening
participation (screening adherence) within 365 days of
Expert meeting
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Figure 1. Flow diagram of the lung cancer screening process implemented by the local government of Yokohama City. In
the primary screening, participants were examined by chest X-ray (indirect or direct radiograph), with or without
additional sputum cytology test. There were two lung cancer screening systems: one was performed in the 18
Public Health and Welfare Centers (PHWC), and the other was in the Cancer Center of Yokohama Municipal
Citizen’s Hospital (CC-YMCH). If participants had positive results (e1, e2, and d) in the primary screening,
they were asked to undergo work-up examinations, such as chest X-ray (direct radiograph), chest computed
tomography (CT), and bronchoscopy.
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determining false-positive or negative results. This study
period was used because the eﬃcacy of lung cancer screening
has been shown to be higher in patients who had undergone
screening within 365 days of case diagnosis.10
Measurements for this study included sex, age, smoking
status, lung comorbidities, occupational history related to
pneumoconiosis, family history of malignancy, current
employment, screening institution, screening fees borne by
participant, period of work-up examinations, and procedures of
work-up examinations. Lung comorbidities included chronic
obstructive pulmonary disease, bronchiectasis, interstitial
pneumonia, asbestosis, sarcoidosis, and pneumoconiosis.
Statistical analysis
We compared participants with false-positive results and those
with negative results. Continuous variables were summarized
as means and standard deviations, and categorical variables
were summarized as proportions. Smoking status was
categorized into three groups: non-smokers, who had never
smoked cigarettes regularly; former smokers, who had
previously smoked cigarettes regularly but were not current
smokers; and current smokers, who smoked cigarettes
regularly at the time of screening attendance. The
proportions of subsequent screening participation were
calculated. Student’s t-test and chi-square test were used to
analyze continuous and categorical variables, respectively.
Statistical signiﬁcance level was set at 5% (two-sided).
Generalized linear regression with a log link, Poisson
distribution, and robust error variances was used to compare
the risk of subsequent participation with the screening results
in the false-positive and negative results groups.19 Age was
divided into 10-year intervals and the period of work-up
examinations was divided into 30-day intervals before these
variables were incorporated into the model. Categorical
variables, except for smoking status, were treated as
dichotomous variables. Measures of association were
reported as risk ratios (RRs) with 95% conﬁdence intervals
(CIs). Covariates in the models were selected through
univariate regression analysis using P values of less than
0.2 as the cutoﬀ value; the ﬁnal models included age, sex,
smoking status, lung comorbidities, occupational history
related to pneumoconiosis, family history of malignancy,
current employment, screening institution, and screening fees.
All potential explanatory variables were assessed for
multicollinearity using the variance inﬂation factor (VIF),
and variables were considered for omission if their VIF was
greater than 5. The interaction between sex and smoking
status was also tested in consideration of the relationship
shown in a previous study.15
A sensitivity analysis was carried out by extending the
duration of the period between primary screening (including
work-up examinations) and subsequent screening participation
to 455 days (1.25 years), 545 days (1.5 years), 635 days (1.75
years) and 730 days (2 years). A subgroup analysis for the
false-positive results group was also conducted to assess the
risk factors for subsequent participation. In the subgroup
analysis, the period and procedures of work-up examinations
were additionally used as covariates for adjustment. All
analyses were performed using STATA version 13 (Stata
corporation, College Station, TX, USA).
RESULTS
Demographic data and background characteristics
A total of 44 644 participants attended the chest X-ray
screening for lung cancer provided by Yokohama City
between April 2007 and March 2011. Among them, 19 588
(44%) were ﬁrst-time screening participants, and 18 869
participants, including 15 737 (83%) with negative results
and 3132 (17%) with false-positive results, were included in
the analysis (Figure 2). As shown in Table 1, there were
statistically signiﬁcant diﬀerences between the negative and
false-positive results groups in sex, age, smoking status,
lung comorbidities, family history of malignancy, current
employment, and screening fees (P < 0.05).
Subsequent screening participation
The proportions of subsequent screening participation were
6.7% and 12.9% in the negative and false-positive results
groups, respectively. The crude risk diﬀerence (false-positive
vs negative) was 0.06 (95% CI, 0.05–0.07), and the crude RR
was 1.92 (95% CI, 1.73–2.14). In the sensitivity analysis
(Figure 3), extending the period between the initial screening
and subsequent screening resulted in reductions to the gaps in
subsequent attendance rates between the negative and false-
positive results groups; however, participants with false-
positive results were still consistently more likely to attend
subsequent screening (P < 0.01).
Predictors of participation in subsequent screening
The multivariable analysis indicated that false-positive results
(RR 1.72; 95% CI, 1.54–1.92), older age (RR 1.17; 95% CI,
1.11–1.23), male sex (RR 1.46; 95% CI, 1.29–1.64), being
a current smoker (RR 0.80; 95% CI, 0.69–0.93), current
employment (RR 0.79; 95% CI, 0.70–0.90), and being
screened at the CC-YMCH (RR 1.36; 95% CI, 1.15–1.60)
were statistically signiﬁcant predictors of participation in
subsequent screening (Table 2). Multicollinearity was not
detected for the variables, and no interaction between sex and
smoking status was observed.
Subgroup analysis for participants with false-
positive results
Table 3 shows the results of the subgroup analysis for
participants with false-positive results. The results indicated
that subsequent participation was positively associated with
male sex (RR 1.34; 95% CI, 1.07–1.69) and being screened at
the CC-YMCH (RR 1.80; 95% CI, 1.35–2.39) and negatively
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associated with being a current smoker (RR 0.72; 95% CI,
0.55–0.96) and current employment (RR 0.79; 95% CI,
0.62–0.99). These results were similar to the analysis for
all participants. In addition, subsequent participation was
positively associated with longer periods of work-up
examinations (RR 1.14; 95% CI, 1.10–1.17).
DISCUSSION
Attendance rates for lung cancer screening is low (about 20%)
in Japan.11 While it is important to encourage participation in
those who have never undergone lung cancer screening, it is
also necessary to focus on screening adherence and encourage
regular screening to maximize the beneﬁts aﬀorded by these
programs. This study revealed a low re-attendance rate after
the ﬁrst-time screening for lung cancer in actual clinical
practice and provides several suggestions to improve these
rates. We demonstrated that participants with false-positive
results were more likely to attend subsequent screening
than participants with negative results. This may be partly
explained by participants with false-positive results having
more opportunities to be encouraged to attend subsequent
screenings by medical professionals and to enhance their
health awareness during their work-up examinations. On
the other hand, participants with negative results are only
















Aged <40 or  ≥80 years
(n=422)












Participants in chest X-ray lung cancer screening
n=44,644 (FY2007-FY2010)
Previously attended screening 




Figure 2. Selection of the study cohort. First-time lung cancer screening participants aged 40–79 years with no personal
history of lung cancer, who had undergone work-up examinations, and who had no bloody sputum were
included in the analysis. The study cohort consisted of 15 737 participants with negative results and 3132
participants with false-positive results. FY, ﬁscal year.
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primary screening. Therefore, a more proactive approach to
ensure regular participation for those with negative results
is needed. In contrast with the ﬁndings of our study,
false-positive results were identiﬁed as a negative predictor
of subsequent screening participation in PLCO study
participants.15 We postulate that this disparity may be
inﬂuenced by the underlying diﬀerences in participant
characteristics (eg, fear of lung cancer and perceived risk
due to radiation exposure) and awareness for cancer screening
(eg, belief in screening eﬀectiveness), as well as by diﬀerent
study designs, health insurance systems, and socio-
psychological conditions.
We also identiﬁed other factors positively associated with
participating in subsequent screening, including male sex,
older age, screening institution, and a longer period of work-
up examinations. Current smoking and current employment
were negatively associated with subsequent screening
participation. Current smokers may be less concerned about
their health in general and therefore less likely to participate in
subsequent screenings. A population-based approach to
promote smoking cessation (eg, oﬀering information on the
merits of smoking cessation) may enhance screening
participation. Employed people might think they are healthy
or prioritize their work rather than participation in screenings.
Improved access to screening (eg, building a remote
diagnostic system) may be helpful for these people.
Participants with longer periods of work-up examinations
may have more opportunities to become familiar with
the physicians and medical staﬀ, so they may develop an
increased awareness of their health.12 In contrast, CT scan and
bronchoscopy may discourage participants from attending
subsequent screenings, despite the lack of statistical
signiﬁcance in the present study, because these procedures
place higher physical, psychological, and economic burdens
on the examinees. These ﬁndings suggest the need for an
individualized approach to facilitating regular screening
participation according to characteristics of participants
and screening methods. A theoretical approach based on
behavioral economics and social marketing can be eﬀectively
applied to determine the individualized strategy to promote
re-attendance to lung cancer screening, but further research
will be needed.20–22
Studies have been conducted on the eﬀects of false-positive
results on breast cancer screening,13,14 which may give insight
into the general underlying issues in cancer screening. A
systematic review showed that participants with false-positive
results in mammography for breast cancer had anxieties
associated with the screening process.14 The participants
with false-positive results in our study may also experience
fear and anxiety associated with inspections that are more
unpleasant or involve higher radiation exposure than the initial
screening test, which may aﬀect participation in subsequent
screenings. In addition to such psychological considerations,
screening intervals, target screening population, and the
screening modalities may also aﬀect screening participation
behaviors. Therefore, it is necessary to evaluate the
eﬀectiveness of cancer screening in real clinical practice
in the context of the various characteristics of screening.
Previous studies of mammography screening indicate that
diﬀerences in psychological backgrounds, social security
systems, and national identity may aﬀect screening
participation.12–14
There are several limitations to this study. First, the
participants included only those who did not have an
opportunity to undergo cancer screening at their workplace
and unemployed people. Thus, our study sample may not be
representative of the entire population that is eligible for
screening. In addition, the analysis may underestimate the rate
of subsequent screening attendance because some participants
may have joined other screening programs after the ﬁrst-time





P value(n = 18869) (n = 15737) (n = 3132)
n (%) n (%) n (%)
Mean (SD) age, years 59.5 (10.8) 58.9 (10.9) 63.4 (9.6) <0.01a
Sex <0.01b
Female 11244 (59.6) 9631 (61.2) 1613 (51.5)
Male 7625 (40.4) 6106 (38.8) 1519 (48.5)
Smoking status <0.01b
Non-smoker 11212 (59.4) 9429 (59.9) 1783 (56.9)
Former smoker 3743 (19.8) 3042 (19.3) 701 (22.4)
Current smoker 3914 (20.7) 3266 (20.8) 648 (20.7)
Lung comorbidity <0.01b
No 17966 (95.2) 15014 (95.4) 2952 (94.2)
Yes 903 (4.8) 723 (4.6) 180 (5.7)
Asthma 689 (3.7) 576 (3.7) 113 (3.6)
COPD 138 (0.7) 99 (0.6) 39 (1.3)
Bronchiectasis 85 (0.5) 60 (0.4) 25 (0.8)
Interstitial pneumonia 9 (0.05) 3 (0.02) 6 (0.2)
Asbestosis 4 (0.02) 2 (0.01) 2 (0.06)
Sarcoidosis 10 (0.03) 3 (0.02) 3 (0.1)
Pneumoconiosis 1 (0.01) 1 (0.01) 0 (0.0)
Occupational history related to pneumoconiosis 0.17b
No 17608 (93.3) 14703 (93.4) 2905 (92.8)
Yes 1261 (6.7) 1034 (6.6) 227 (7.2)
Family history of malignancy <0.01b
No 6452 (34.2) 5302 (33.7) 1150 (36.7)
Yes (any type of malignancy) 12417 (65.8) 10435 (66.3) 1982 (63.3)
Lung cancer 2466 (13.1) 2074 (13.2) 392 (12.5) 0.32b
Employment status <0.01b
No 12656 (67.1) 10443 (66.4) 2213 (70.7)
Yes 6213 (32.9) 5294 (33.6) 919 (29.3)
Screened at CC-YMCH 0.11b
No 15688 (83.1) 13115 (83.3) 2573 (82.2)
Yes 3181 (16.9) 2622 (16.7) 559 (17.8)
Screening fees borne by participant 0.02b
No 1572 (8.3) 1278 (8.1) 294 (9.4)
Yes 17297 (91.7) 14459 (91.9) 2838 (90.6)
Procedures of work-up examinations
No — — 40 (1.3)
Chest X-ray (direct radiograph) — — 2363 (75.4)
Chest computed tomography — — 1794 (57.3)
Bronchoscopy — — 58 (1.9)
CC-YMCH, Cancer Center of Yokohama Municipal Citizen’s Hospital;




There was no missing data for study cohort characteristics. Data are
presented as n (%), unless otherwise noted.
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screening. Second, we attempted to restrict our analysis to
ﬁrst-time screening participants with at least 5 years of non-
attendance to the screening program. However, the sample
may also include participants who have irregularly attended
the screening program and had undergone screening more
than 5 years prior. Third, this study could not provide insight
into the reasons for failure to attend subsequent screening.
Reasons for non-attendance may include death, re-location,
and participation in other screening programs or medical
check-ups. Psychological, economic, and other factors may
also aﬀect screening attendance, and we should consider these
aspects when evaluating the eﬀectiveness of the screening
process. Fourth, Yokohama City is one of the most urbanized
areas in Japan, and there may be diﬃculties in extrapolating
our results to smaller, more rural areas due to diﬀerences
in access to medical facilities. Finally, and possibly most
importantly, we assumed the eﬀectiveness of the screening test
itself based only on evidence from case-control studies
conducted in Japan,5–10 despite conﬂicting results from
studies conducted in other countries. Chest X-ray screening
for lung cancer has not been shown to reduce lung cancer
mortality
in the United States or Europe.23–27 There has yet to be a
randomized controlled trial conducted in Japan to evaluate
the eﬀectiveness of chest X-ray screening for lung cancer.
In conclusion, this study demonstrated that subsequent
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Figure 3. Sensitivity analysis of subsequent participation in lung cancer screening. The proportion of participants with
subsequent screening participation was consistently higher in participants with false-positive results compared
to those with negative results, even when the duration of the period between primary screening and subsequent
screening was extended. However, the diﬀerences in proportions of participants with subsequent screening
participation were reduced as longer durations were applied.
Table 3. Predictors of participation in subsequent screening
based on multivariable regression analysis for
participants with false-positive results
Variables Reference RR (95% CI)
Age (10-year increments) 1.08 (0.97–1.21)
Male Female 1.34 (1.07–1.69)
Smoking status
Former smoker Non-smoker 0.81 (0.62–1.04)
Current smoker Non-smoker 0.72 (0.55–0.96)




Family history of malignancy None 0.98 (0.81–1.19)
Current employment None 0.79 (0.62–0.99)
Screened at CC-YMCH Screened at PHWC 1.80 (1.35–2.39)
Screening fee borne by participant Exempted 0.98 (0.69–1.39)
Period of work-up examinations
(30-day increments)
1.14 (1.10–1.17)





CC-YMCH, Cancer Center of Yokohama Municipal Citizen’s Hospital;
CI, conﬁdence interval; PHWC, Public Health and Welfare Center;
RR, risk ratio.
Table 2. Predictors of participation in subsequent screening
based on univariable and multivariable regression
analysis for the overall study population
Variables Reference
Univariable Multivariable
RR (95% CI) RR (95% CI)
False-positive result Negative result 1.92 (1.73–2.14) 1.72 (1.54–1.92)
Age (10-year increments) 1.28 (1.22–1.33) 1.17 (1.11–1.23)
Male Female 1.42 (1.29–1.56) 1.46 (1.29–1.64)
Smoking status
Former smoker Non-smoker 1.09 (0.97–1.23) 0.90 (0.79–1.03)
Current smoker Non-smoker 0.84 (0.73–0.95) 0.80 (0.69–0.93)
Lung comorbidity None 0.91 (0.72–1.16) 0.95 (0.75–1.20)
Occupational history related
to pneumoconiosis
None 0.88 (0.72–1.08) 0.82 (0.66–1.01)
Family history of malignancy None 0.95 (0.86–1.05) 1.00 (0.90–1.11)
Current employment None 0.73 (0.65–0.81) 0.79 (0.70–0.90)
Screened at CC-YMCH Screened at PHWC 1.25 (1.11–1.41) 1.36 (1.15–1.60)
Screening fee borne by
participant
Exempted 0.79 (0.68–0.93) 1.07 (0.86–1.33)
CC-YMCH, Cancer Center of Yokohama Municipal Citizen’s Hospital;
CI, conﬁdence interval; PHWC, Public Health and Welfare Center;
RR, risk ratio.
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practice was aﬀected by the initial screening result and several
patient characteristics. The predictors identiﬁed in this study
may be useful for selecting the target population that should
be actively encouraged to attend subsequent screenings. In
Japan, there is a great need to improve cancer screening rates,
and our ﬁndings may support the formulation of proactive
measures to facilitate continuous and consistent participation
in lung cancer screening.
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